(Q52238849)

27 April 2018

title

The effect of ondansetron on cognitive performance in the marmoset (English)

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

3 December 2022

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

3 December 2022

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

3 December 2022

author name string

A. M. Domeney

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826787

3 December 2022

B. Costall

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826787

3 December 2022

P. A. Gerrard

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826787

3 December 2022

D. N. Jones

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826787

3 December 2022

R. J. Naylor

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826787

3 December 2022

M. B. Tyers

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1826787

3 December 2022

language of work or name

English

0 references

publication date

1 January 1991

1 reference

27 April 2018

full work available at URL

https://api.elsevier.com/content/article/PII:0091305791906063?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

https://api.elsevier.com/content/article/PII:0091305791906063?httpAccept=text/plain

3 December 2022

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Pharmacology, Biochemistry and Behavior

3 December 2022

published in

1 reference

27 April 2018

volume

38

1 reference

27 April 2018

issue

1

1 reference

27 April 2018

page(s)

169-175

1 reference

27 April 2018

[3H]zacopride: ligand for the identification of 5-HT3 recognition sites

cites work

3

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Identification of 5-HT3 recognition sites in human brain tissue using [3H]zacopride

3 December 2022

4

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissue

3 December 2022

5

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Biochemical Assessment of Serotonergic and Cholinergic Dysfunction and Cerebral Atrophy in Alzheimer's Disease

3 December 2022

7

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors

3 December 2022

8

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia

3 December 2022

9

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain

3 December 2022

10

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Zacopride: anxiolytic profile in rodent and primate models of anxiety

3 December 2022

11

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Somatostatin content and release measured in cerebral biopsies from demented patients.

3 December 2022

15

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain

3 December 2022

17

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

The potential anxiolytic activity of GR38032F, a 5-HT3-receptor antagonist

3 December 2022

18

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

3 December 2022

Alzheimer's disease

19

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding

3 December 2022

20

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species

3 December 2022

21

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

3 December 2022

Cognition activators

22

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Intravenous nicotine in Alzheimer's disease: a pilot study.

3 December 2022

23

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Presynaptic serotonergic dysfunction in patients with Alzheimer's disease

3 December 2022

24

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Species variations in 5-HT3 recognition sites labeled by 3H-quipazine in the central nervous system

3 December 2022

25

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Reduced binding of [3H]ketanserin to cortical 5-HT2 receptors in senile dementia of the Alzheimer type

3 December 2022

26

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

An analysis of visual object reversal learning in the marmoset after amphetamine and haloperidol.

3 December 2022

27

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Effects of ibotenic acid lesions of the basal forebrain on serial reversal learning in marmosets

3 December 2022

28

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Visuospatial learning impairment following lesion of the cholinergic projection to the hippocampus

3 December 2022

29

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease

3 December 2022

30

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Impairment in T-maze reinforced alternation performance following nucleus basalis magnocellularis lesions in rats

3 December 2022

31

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

3 December 2022

32

1 reference

https://api.crossref.org/works/10.1016/0091-3057(91)90606-3

3 December 2022

Identifiers

1 reference

27 April 2018

1 reference

27 April 2018